Mersana Therapeutics Receives $33,000,000 Series C Financing

  • Feed Type
  • Date
  • Company Name
    Mersana Therapeutics
  • Mailing Address
    840 Memorial Drive Cambridge, MA 02139 USA
  • Company Description
    Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    Mersana plans to use the proceeds to further develop its pipeline programs and expand its proprietary ADC platform. The Company currently anticipates filing an Investigational New Drug (IND) application for lead candidate XMT-1522, a novel HER-2 targeting therapy, in mid-2016, and plans to initiate a Phase 1 proof of concept clinical trial shortly thereafter. Mersana’s second program, XMT-1536, a novel anti-sodium-dependent phosphate transport protein 2B (anti-NaPi2b) ADC, is currently advancing into IND-enabling studies.
  • M&A Terms
  • Venture Investor
    Wellington Management Company
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    Arrowpoint Partners
  • Venture Investor
    Takeda Ventures
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Rock Springs Capital

Trending on Xconomy